CN100563653C - 具有β-内酰胺酶抑制剂活性的杂环化合物 - Google Patents

具有β-内酰胺酶抑制剂活性的杂环化合物 Download PDF

Info

Publication number
CN100563653C
CN100563653C CNB2007100015952A CN200710001595A CN100563653C CN 100563653 C CN100563653 C CN 100563653C CN B2007100015952 A CNB2007100015952 A CN B2007100015952A CN 200710001595 A CN200710001595 A CN 200710001595A CN 100563653 C CN100563653 C CN 100563653C
Authority
CN
China
Prior art keywords
oxo
octane
diazabicyclo
oxygen base
dichloromethane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB2007100015952A
Other languages
English (en)
Chinese (zh)
Other versions
CN1994301A (zh
Inventor
J·奥索迪
C·弗罗芒坦
M·兰皮拉斯
D·A·罗兰兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca SAS
Wyeth Research Ireland Ltd
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27619669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN100563653(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of CN1994301A publication Critical patent/CN1994301A/zh
Application granted granted Critical
Publication of CN100563653C publication Critical patent/CN100563653C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB2007100015952A 2002-01-28 2003-01-27 具有β-内酰胺酶抑制剂活性的杂环化合物 Expired - Lifetime CN100563653C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0200951A FR2835186B1 (fr) 2002-01-28 2002-01-28 Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR02/00951 2002-01-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB038028786A Division CN100482225C (zh) 2002-01-28 2003-01-27 具有β-内酰胺酶抑制剂活性的新的杂环化合物

Publications (2)

Publication Number Publication Date
CN1994301A CN1994301A (zh) 2007-07-11
CN100563653C true CN100563653C (zh) 2009-12-02

Family

ID=27619669

Family Applications (3)

Application Number Title Priority Date Filing Date
CNB2007100015952A Expired - Lifetime CN100563653C (zh) 2002-01-28 2003-01-27 具有β-内酰胺酶抑制剂活性的杂环化合物
CNB038028786A Expired - Lifetime CN100482225C (zh) 2002-01-28 2003-01-27 具有β-内酰胺酶抑制剂活性的新的杂环化合物
CNA2008101667591A Pending CN101406471A (zh) 2002-01-28 2003-01-27 具有β-内酰胺酶抑制剂活性的新的杂环化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CNB038028786A Expired - Lifetime CN100482225C (zh) 2002-01-28 2003-01-27 具有β-内酰胺酶抑制剂活性的新的杂环化合物
CNA2008101667591A Pending CN101406471A (zh) 2002-01-28 2003-01-27 具有β-内酰胺酶抑制剂活性的新的杂环化合物

Country Status (45)

Country Link
US (4) US7612087B2 (https=)
EP (2) EP2279737B1 (https=)
JP (1) JP4472346B2 (https=)
KR (1) KR100979079B1 (https=)
CN (3) CN100563653C (https=)
AR (2) AR038234A1 (https=)
AT (1) ATE484281T1 (https=)
AU (1) AU2003214335B2 (https=)
BE (1) BE2016C069I2 (https=)
BR (1) BRPI0307267B8 (https=)
CA (1) CA2474043C (https=)
CL (1) CL2011000009A1 (https=)
CO (1) CO5601014A2 (https=)
CR (2) CR7387A (https=)
CY (3) CY1111061T1 (https=)
DE (1) DE60334527D1 (https=)
DK (2) DK2279737T3 (https=)
EA (1) EA007220B1 (https=)
EC (1) ECSP045193A (https=)
ES (2) ES2356813T3 (https=)
FR (2) FR2835186B1 (https=)
HR (1) HRP20040686B1 (https=)
HU (1) HUS1600055I1 (https=)
IL (1) IL163167A (https=)
JO (1) JO2646B1 (https=)
LT (1) LTC1480644I2 (https=)
MA (1) MA26351A1 (https=)
MX (1) MXPA04006621A (https=)
MY (1) MY140638A (https=)
NL (1) NL300847I2 (https=)
NO (3) NO335195B1 (https=)
NZ (1) NZ533936A (https=)
OA (1) OA12761A (https=)
PE (1) PE20030969A1 (https=)
PL (1) PL220725B1 (https=)
PT (2) PT2279737E (https=)
PY (1) PY0301561A (https=)
RS (1) RS52137B (https=)
SI (2) SI2279737T1 (https=)
TN (1) TNSN04137A1 (https=)
TW (1) TWI293071B (https=)
UA (1) UA80271C2 (https=)
UY (1) UY27626A1 (https=)
WO (1) WO2003063864A2 (https=)
ZA (1) ZA200405607B (https=)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2844273B1 (fr) 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
US7439253B2 (en) * 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2848210B1 (fr) * 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
US8900637B2 (en) * 2005-12-02 2014-12-02 Lupin Limited Stable taste masked formulations of cephalosporins
CA2783572C (en) * 2005-12-07 2016-08-09 Basilea Pharmaceutica Ag Useful combinations of monobactam antibiotics with beta-lactamase inhibitors
EP2040698A4 (en) * 2006-07-14 2011-08-10 Shionogi & Co OXIM CONNECTIONS AND ITS USE
WO2008051763A1 (en) * 2006-10-23 2008-05-02 Irm Llc Cathepsin proteases inhibitors
US8563732B2 (en) * 2007-05-31 2013-10-22 Shionogi & Co., Ltd. Oxyimino compounds and the use thereof
FR2921060B1 (fr) * 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
ES2533826T3 (es) * 2008-01-18 2015-04-15 Merck Sharp & Dohme Corp. Inhibidores de beta-lactamasa
US20110046101A1 (en) * 2008-03-17 2011-02-24 Dmitrienko Gary I Bate-lactamase inhibitors
FR2930553B1 (fr) * 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
EP2346820B1 (en) * 2008-06-11 2013-02-13 Shionogi & Co., Ltd. Oxycarbamoyl compounds and the use thereof
FR2936798B1 (fr) * 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2937034B1 (fr) * 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2936951B1 (fr) * 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2951171A1 (fr) * 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
AU2014244235B2 (en) * 2009-10-09 2016-04-21 Pfizer Ireland Pharmaceuticals Polymorphic and pseudopolymorphic forms of a pharmaceutical compound
RS60310B1 (sr) 2010-08-10 2020-07-31 Rempex Pharmaceuticals Inc Ciklični derivati estra boronske kiseline, postupak za pripremu injihove terapeutske upotrebe
SI2657234T1 (sl) * 2010-12-22 2017-06-30 Meiji Seika Pharma Co., Ltd. Derivat optično-aktivnega diazabiciklooktana in metoda za njegovo izdelavo
US8772490B2 (en) * 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
KR102143660B1 (ko) * 2011-06-17 2020-08-11 화이자 안티-인펙티브스 에이비 트랜스-7-옥소-6-(술포옥시)-1,6-디아자비시클로[3,2,1]옥탄-2-카르복스아미드 및 그의 염을 포함하는 헤테로시클릭 화합물의 제조 방법
RU2578370C2 (ru) * 2011-08-27 2016-03-27 Вокхардт Лимитед Производные 1,6- диазабицикло [3,2,1] октан-7-она и их применение при лечении бактериальных инфекционных болезней
US20130053565A1 (en) * 2011-08-29 2013-02-28 University Of Utah Research Foundation Substituted 3-piperidone compounds
US9102683B2 (en) 2011-08-29 2015-08-11 University Of Utah Research Foundation Heterocyclic compounds
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
EP3052497B1 (en) * 2011-09-13 2017-06-28 Wockhardt Limited Nitrogen containing compounds and their use
US8969567B2 (en) * 2011-09-13 2015-03-03 Wockhardt Ltd. Nitrogen containing compounds and their use
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
TW201343645A (zh) 2012-03-30 2013-11-01 Cubist Pharm Inc １，３，４－□二唑及１，３，４－噻二唑β－內醯胺酶抑制劑
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
KR20150003777A (ko) 2012-03-30 2015-01-09 큐비스트 파마슈티컬즈 인코포레이티드 이속사졸 β-락타마제 억제제
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
RU2693898C2 (ru) 2012-05-30 2019-07-05 Мейдзи Сейка Фарма Ко., Лтд. НОВЫЙ ИНГИБИТОР бета-ЛАКТАМАЗЫ И СПОСОБ ЕГО ПОЛУЧЕНИЯ
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
BR112015003592B1 (pt) * 2012-08-25 2020-04-14 Wockhardt Ltd derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas
UA111925C2 (uk) * 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
KR20150103270A (ko) 2013-01-04 2015-09-09 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
KR20150103269A (ko) 2013-01-04 2015-09-09 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
US9120795B2 (en) 2013-03-14 2015-09-01 Cubist Pharmaceuticals, Inc. Crystalline form of a β-lactamase inhibitor
DK3050883T3 (da) 2013-09-24 2020-05-25 Meiji Seika Pharma Co Ltd Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
EP3613740A1 (en) 2013-10-08 2020-02-26 Meiji Seika Pharma Co., Ltd. Preparation of a diazabicyclooctane derivative
JP2017506240A (ja) * 2014-02-20 2017-03-02 ウォックハート リミテッド 抗菌剤を含む医薬組成物
CN103896936A (zh) * 2014-03-20 2014-07-02 西安交通大学 (5s,6r)氯唑西林青霉噻唑酸盐及其制备方法和应用
EP3139930B1 (en) 2014-05-05 2024-08-14 Melinta Therapeutics, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
SI3140310T1 (sl) 2014-05-05 2020-01-31 Rempex Pharmaceuticals, Inc. Sinteza boronatnih soli in njihova uporaba
WO2015179308A1 (en) 2014-05-19 2015-11-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN104059083B (zh) * 2014-05-27 2017-01-04 浙江工业大学 一种手性二环己内酰胺类化合物的不对称合成方法
EA201692301A1 (ru) 2014-07-01 2017-06-30 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
KR102542392B1 (ko) * 2014-11-17 2023-06-09 엔타시스 테라퓨틱스 리미티드 내성 박테리아 감염의 치료를 위한 배합물 치료제
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
RU2732129C2 (ru) 2014-12-05 2020-09-11 Мейдзи Сейка Фарма Ко., Лтд. Способ производства кристаллов производного диазабициклооктана и стабильного лиофилизированного препарата
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CA2983674A1 (en) * 2015-05-07 2016-11-10 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
EP3281942A4 (en) * 2015-09-16 2018-08-15 Xuanzhu Pharma Co., Ltd. B-lactamase inhibitor and application thereof
CA3000087A1 (en) 2015-10-02 2017-04-06 Legochem Biosciences, Inc. Compositions and methods for inhibiting beta-lactamase
WO2017156458A1 (en) 2016-03-11 2017-09-14 University Of South Florida Beta-lactamase inhibitors, formulations, and uses thereof
ES2734773T3 (es) 2016-05-27 2019-12-11 Valoralia I Mas D Sl Compuestos de dihidrooxadiazina para tratar infecciones y cáncer
ES2894251T3 (es) 2016-06-30 2022-02-14 Qpex Biopharma Inc Derivados de ácido borónico y usos terapéuticos de los mismos
CN106279163A (zh) * 2016-08-12 2017-01-04 上海龙翔生物医药开发有限公司 一种合成阿维巴坦及其中间体光学异构体的方法
CN107789355B (zh) * 2016-09-07 2022-04-12 湘北威尔曼制药股份有限公司 含有哌拉西林的复方药物组合物及其应用
CN114591223B (zh) 2016-09-16 2025-01-24 恩塔西斯治疗有限公司 β-内酰胺酶抑制剂化合物
JOP20190061A1 (ar) * 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
CN106699756B (zh) * 2016-12-30 2019-10-29 淄博鑫泉医药技术服务有限公司 β内酰胺酶抑制剂阿维巴坦的合成方法
KR20190115062A (ko) 2017-02-06 2019-10-10 무타빌리스 새로운 헤테로사이클릭 화합물 및 이의 세균 감염 치료 또는 예방 용도
NZ758200A (en) 2017-05-08 2025-12-19 Entasis Therapeutics Inc Compounds and methods for treating bacterial infections
WO2018234962A1 (en) 2017-06-20 2018-12-27 Wockhardt Limited Process for o-sulfonation of 1,6-diazabicyclo[3.2.1]octane compounds
MX2020003495A (es) 2017-10-11 2020-09-18 Qpex Biopharma Inc Derivados de acido boronico y sintesis de los mismos.
CN109678856B (zh) * 2017-10-18 2020-09-25 新发药业有限公司 一种阿维巴坦中间体的制备方法
WO2019093450A1 (ja) * 2017-11-10 2019-05-16 塩野義製薬株式会社 ジアザビシクロオクタン誘導体
US12016868B2 (en) 2018-04-20 2024-06-25 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
SG11202101255UA (en) 2018-08-09 2021-03-30 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN109942579B (zh) * 2019-04-18 2021-06-22 成都千禧莱医药科技有限公司 β-内酰胺酶抑制剂含脲双环化合物及其制备方法和应用
BR112022022367A2 (pt) 2020-05-05 2023-01-10 Qpex Biopharma Inc Derivados e síntese de ácido borônico, formas polimórficas e usos terapêuticos dos mesmos
EP4146650B1 (en) * 2020-09-01 2026-01-21 Ningxia Academy of Agriculture and Forestry Sciences Beta-lactamase inhibitors and their preparation
WO2022047790A1 (en) * 2020-09-07 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Amidine substituted bicyclic compounds, their preparation, their use as antibacterial agents and beta-lactamase inhibitors
US12410166B2 (en) 2021-05-07 2025-09-09 Ningxia Academy Of Agriculture And Forestry Sciences Sulfonylamidine substituted compounds and their use as beta-lactamase inhibitors
WO2023060369A1 (en) * 2021-10-11 2023-04-20 Ningxia Academy Of Agriculture And Forestry Sciences Novel carbimidate substituted bicyclic compounds and their use as beta-lactamase inhibitors
KR20240041506A (ko) 2022-09-23 2024-04-01 주식회사 경보제약 아비박탐 나트륨 염의 안정한 일수화물 형태 및 그의 제조 방법
CN116375706B (zh) * 2023-02-22 2025-02-14 时森海(杭州)医药科技有限公司 阿维巴坦钠关键中间体及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0260057A3 (en) 1986-09-02 1989-02-01 The University Of Melbourne 2-oxo-4-carboxy-pyrimidines
KR0167346B1 (ko) 1989-06-09 1999-01-15 로버트 에이. 아미테이지 중추신경계 활성을 갖는 헤테로사이클릭 아민
FR2676230B1 (fr) 1991-05-07 1993-08-27 Centre Nat Rech Scient Nouveaux derives de pyrrolo [1,4]-benzodiazepines, leur procede de preparation et medicaments les contenant.
JPH05339263A (ja) 1992-06-08 1993-12-21 Wakunaga Pharmaceut Co Ltd ジヒドロピリジン誘導体
ES2182847T3 (es) 1993-09-29 2003-03-16 Nabi Nucleosidos y nucleotidos de anillo expandido.
HUT74682A (en) * 1993-12-29 1997-01-28 Pfizer Diazabicyclic neurokinin antagonists and pharmaceutical compositions containing them
EP0702004A2 (de) 1994-09-15 1996-03-20 Ciba-Geigy Ag 2,9-Diamino- und 2-amino-8-carbamoyl-4-hydroxy-alkansäureamid-derivative
GB9505538D0 (en) 1995-03-18 1995-05-03 Ciba Geigy Ag New compounds
SE9504618D0 (sv) 1995-12-22 1995-12-22 Astra Ab New Compounds
JP4163254B2 (ja) * 1996-01-03 2008-10-08 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ムチリンのカルバモイルオキシ誘導体および抗細菌剤としてのそれらの使用
UA51716C2 (uk) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
HUP0001741A3 (en) * 1996-08-02 2000-11-28 Smithkline Beecham Plc Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use, process for preparing them, pharmaceuticals contg. them and their use
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
US5994340A (en) * 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
US6197339B1 (en) 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
UY25225A1 (es) * 1997-10-29 2000-12-29 Smithkline Beecham Plc Derivados de pleuromutilina utiles como agentes antimicrobianos
EP1070054A1 (en) 1998-04-08 2001-01-24 Takeda Chemical Industries, Ltd. Amine compounds, their production and their use as somatostatin receptor antagonists or agonists
AU4698399A (en) 1998-06-30 2000-01-17 Du Pont Pharmaceuticals Company 1,3-benzodiazepin-2-ones and 1,3-benzoxazepin-2-ones useful as hiv reverse transcriptase inhibitors
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
TR200101754T2 (tr) 1998-12-18 2002-05-21 Schering Corporation Farnezil protein transferaz inhibitörleri
CO5180550A1 (es) 1999-04-19 2002-07-30 Smithkline Beecham Corp Inhibidores de fab i
AU7556800A (en) 1999-10-07 2001-05-10 Tadeka Chemical Industries, Ltd. Amine derivatives
EP1288216A1 (en) 2000-04-18 2003-03-05 Sumitomo Pharmaceuticals Company, Limited Tricyclic quinazolinediones
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
US7179921B2 (en) 2001-02-22 2007-02-20 School Of Pharmacy, University Of London Indoline and tetrahydro-quinolines as prodrugs for tumour treatment
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US7439253B2 (en) * 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors

Also Published As

Publication number Publication date
LTPA2016037I1 (lt) 2017-01-10
CN101406471A (zh) 2009-04-15
MY140638A (en) 2010-01-15
OA12761A (fr) 2006-07-04
FR16C1019I2 (fr) 2017-12-29
DE60334527D1 (de) 2010-11-25
LTC1480644I2 (lt) 2018-09-10
KR20040081473A (ko) 2004-09-21
PT1480644E (pt) 2011-01-17
HK1105864A1 (zh) 2008-02-29
HRP20040686A2 (en) 2004-12-31
US20090215747A1 (en) 2009-08-27
CY1114417T1 (el) 2016-08-31
NO2016024I1 (no) 2016-12-15
AR100790A2 (es) 2016-11-02
IL163167A (en) 2010-04-15
WO2003063864A2 (fr) 2003-08-07
EA200400981A1 (ru) 2005-02-24
JP4472346B2 (ja) 2010-06-02
JP2005523897A (ja) 2005-08-11
CY1111061T1 (el) 2015-06-11
AU2003214335B2 (en) 2007-04-05
ZA200405607B (en) 2005-09-28
NO335195B1 (no) 2014-10-20
US20100048528A1 (en) 2010-02-25
CY2016042I2 (el) 2017-03-15
UY27626A1 (es) 2003-08-29
CA2474043C (fr) 2011-08-02
ES2401855T3 (es) 2013-04-25
CN100482225C (zh) 2009-04-29
US7612087B2 (en) 2009-11-03
NL300847I2 (https=) 2017-01-03
HUS1600055I1 (hu) 2017-01-30
ES2356813T3 (es) 2011-04-13
FR16C1019I1 (fr) 2017-02-03
PL371601A1 (pl) 2005-06-27
CO5601014A2 (es) 2006-01-31
CL2011000009A1 (es) 2011-03-25
US20050020572A1 (en) 2005-01-27
YU65804A (sh) 2006-08-17
DK1480644T3 (da) 2011-01-24
AR038234A1 (es) 2005-01-05
HRP20040686B1 (hr) 2013-02-28
NO2025027I1 (no) 2025-06-13
NZ533936A (en) 2007-05-31
EP2279737A1 (fr) 2011-02-02
BE2016C069I2 (https=) 2022-05-17
PY0301561A (es) 2013-03-01
DK2279737T3 (da) 2013-02-11
TNSN04137A1 (fr) 2007-03-12
TWI293071B (en) 2008-02-01
HK1077205A1 (zh) 2006-02-10
UA80271C2 (uk) 2007-09-10
RS52137B (sr) 2012-08-31
CR7387A (es) 2010-10-25
BR0307267A (pt) 2004-12-07
SI2279737T1 (sl) 2013-07-31
FR2835186A1 (fr) 2003-08-01
BRPI0307267B1 (pt) 2016-02-10
SI1480644T1 (sl) 2011-03-31
CA2474043A1 (fr) 2003-08-07
PE20030969A1 (es) 2003-12-12
TW200303305A (en) 2003-09-01
MXPA04006621A (es) 2004-10-04
CY2016042I1 (el) 2017-03-15
CN1994301A (zh) 2007-07-11
EA007220B1 (ru) 2006-08-25
US20110245254A1 (en) 2011-10-06
BRPI0307267B8 (pt) 2021-05-25
ECSP045193A (es) 2004-08-27
KR100979079B1 (ko) 2010-08-31
EP2279737B1 (fr) 2012-10-31
ATE484281T1 (de) 2010-10-15
PT2279737E (pt) 2013-02-01
FR2835186B1 (fr) 2006-10-20
CN1655781A (zh) 2005-08-17
EP1480644B1 (fr) 2010-10-13
PL220725B1 (pl) 2015-12-31
JO2646B1 (en) 2012-06-17
MA26351A1 (fr) 2004-10-01
NO2016024I2 (no) 2016-12-15
NO20043587L (no) 2004-08-27
CR20120356A (es) 2012-10-05
EP1480644A2 (fr) 2004-12-01
WO2003063864A3 (fr) 2004-03-11

Similar Documents

Publication Publication Date Title
CN100563653C (zh) 具有β-内酰胺酶抑制剂活性的杂环化合物
KR100632906B1 (ko) 아자비시클릭 화합물, 그의 제조 및 약제, 특히항균제로서의 용도
JP2009526767A (ja) 新規二級アミン
JP4297972B2 (ja) 新規なピペリジンカルボン酸アミド誘導体
HK1105864B (en) Heterocyclic compounds which are active as inhibitors of beta-lactamases
HK1077205B (en) Novel heterocyclic compounds which are active as inhibitors of beta+lactamases
EP3075734A1 (en) Heterocyclic compounds and their use in preventing or treating bacterial infections
HK40100308A (zh) 用於治疗炎症性疾病或癌症的氧代二氢吲哚化合物
HK1118822A (en) Novel piperidine carboxylic acid amide derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1105864

Country of ref document: HK

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20081212

Address after: Bonneville, France

Applicant after: Novexel

Address before: French Anthony

Applicant before: AVENTIS PHARMA S.A.

ASS Succession or assignment of patent right

Owner name: NOVELCO SALE CO.,LTD.

Free format text: FORMER OWNER: AVENTIS PHARMA SA

Effective date: 20081212

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1105864

Country of ref document: HK

TR01 Transfer of patent right

Effective date of registration: 20170428

Address after: The Irish Village

Patentee after: Wyeth Research Ireland Ltd.

Address before: France Courbet Wa

Patentee before: AstraZeneca France Holdings Ltd.

Effective date of registration: 20170428

Address after: France Courbet Wa

Patentee after: AstraZeneca France Holdings Ltd.

Address before: French Roman

Patentee before: Novexel

TR01 Transfer of patent right
CX01 Expiry of patent term

Granted publication date: 20091202

CX01 Expiry of patent term